Marker Therapeutics Inc (MRKR)

[Gatta-git-it]

The 3rd qtr conference call citing promising results for orphan drug MT 401 treating the deadly AML disease ( which would be great to those patients) was met with a lower share price this morning. Why?
Past history of failure to produce treatment for (the cancelled) TPIV 200 Ovarian cancer and no update on the TPIV 200 breast cancer treatment ( read Peter H.comments at Q3,1919, Nov.19).. and a cumulative loss if $347 million.. and two years of no updates?

Or, as there are less than 2000 new AML cases each year, the company has not released how much it would have to charge or patient treatment at a 50% penetration rate. Yes, this is important to institutional and retail investors.
Would it be something like 1,000 pts x $100,000, less 30% charity write off?
I try to ask honest questions and not " sing a company song."

Peter has a lot to learn about public relations and share price. I now know the silence if past two years.. they had nkthing.. and what were all those conferences for? But, honestly, if AML and breast cancer could be cured or life pringrd.. that would be worth investing in... make me a believer or enable me to do so. Please... and PH, thoughts?